Resistance to hepatitis C virus protease inhibitors

Current Opinion in Virology

Volumn 8, Issue , 2014, Pages 16-21

  Kieffer, Tara L ^a   George, Shelley ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 450; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; FALDAPREVIR; HEPATITIS C VIRUS PROTEASE INHIBITOR; MK 5172; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS GENOME; VIRUS RESISTANCE; DRUG COMBINATION; DRUG EFFECTS; GENETIC SELECTION; GENETICS; HEPACIVIRUS; HUMAN; PROCEDURES;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HUMANS; PROTEASE INHIBITORS; SELECTION, GENETIC;

EID: 84901318422     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.04.008     Document Type: Review

References (34)

1. N.H. Afdhal The natural history of hepatitis C Semin Liver Dis 24 Suppl 2004 3 8 (Pubitemid 39180700)
2. S. Pol, A. Vallet-Pichard, M. Corouge, V.O. Mallet, and Hepatitis C: epidemiology, diagnosis, natural history and therapy Contrib Nephrol 176 2012 1 9
3. Olysio [Prescribing Information] 2013 Janssen Therapeutics Titusville, NJ
4. Incivek [Prescribing Information] 2013 Vertex Pharmaceuticals Incorporated Cambridge, MA
5. Victrelis [Prescribing Information] 2011 Schering Corporation Whitehouse Station, NJ
6. V. Summa, S.W. Ludmerer, J.A. McCauley, C. Fandozzi, C. Burlein, G. Claudio, P.J. Coleman, J.M. Dimuzio, M. Ferrara, and M. Di Filippo et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
7. V.C. Clark, J.A. Peter, and D.R. Nelson New therapeutic strategies in HCV: second-generation protease inhibitors Liver Int 33 Suppl 1 2013 80 84
8. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107 (Pubitemid 28471138)
9. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
10. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H.M. Chu, and C. Lin et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777 (Pubitemid 46677938)
11. T.L. Kieffer, C. Sarrazin, J.S. Miller, M.W. Welker, N. Forestier, H.W. Reesink, A.D. Kwong, and S. Zeuzem Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631 639 (Pubitemid 47436107)
12. J. Vermehren, and C. Sarrazin The role of resistance in HCV treatment Best Pract Res Clin Gastroenterol 26 2012 487 503
13. R.B. Perni, S.J. Almquist, R.A. Byrn, G. Chandorkar, P.R. Chaturvedi, L.F. Courtney, C.J. Decker, K. Dinehart, C.A. Gates, and S.L. Harbeson et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 50 2006 899 909 (Pubitemid 43327793)
14. B.A. Malcolm, R. Liu, F. Lahser, S. Agrawal, B. Belanger, N. Butkiewicz, R. Chase, F. Gheyas, A. Hart, and D. Hesk et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob Agents Chemother 50 2006 1013 1020 (Pubitemid 43327807)
15. P.M. Scola, A.X. Wang, A.C. Good, L.Q. Sun, K.D. Combrink, J.A. Campbell, J. Chen, Y. Tu, N. Sin, and B.L. Venables et al. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection J Med Chem 57 2014 1708 1729
16. P.W. White, M. Llinas-Brunet, M. Amad, R.C. Bethell, G. Bolger, M.G. Cordingley, J. Duan, M. Garneau, L. Lagace, and D. Thibeault et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease Antimicrob Agents Chemother 54 2010 4611 4618
17. P. Raboisson, H. de Kock, A. Rosenquist, M. Nilsson, L. Salvador-Oden, T.I. Lin, N. Roue, V. Ivanov, H. Wahling, and K. Wickstrom et al. Structure-activity relationship study on a novel series of cyclopentane- containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350 Bioorg Med Chem Lett 18 2008 4853 4858
18. M. Jiang, N. Mani, C. Lin, A. Ardzinski, M. Nelson, D. Reagan, D. Bartels, Y. Zhou, O. Nicolas, and B.G. Rao et al. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir Antimicrob Agents Chemother 57 2013 6236 6245
19. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, and R. Flisiak et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
20. US Food and Drug Administration: Antiviral Drugs Advisory Committee Meeting: Briefing Document: Simeprevir (TMC435): Treatment of Patients with Chronic Hepatitis C: NDA 205123 2013, October Available at http://www.fda.gov/ downloads/advisorycommittees/committeesmeetingmaterials/drugs/ antiviraldrugsadvisorycommittee/ucm371624.pdf (accessed 26.03.14)
21. T.L. Kieffer, S. De Meyer, D.J. Bartels, J.C. Sullivan, E.Z. Zhang, A. Tigges, I. Dierynck, J. Spanks, J. Dorrian, and M. Jiang et al. Hepatitis C, viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials PLoS ONE 7 2012 e34372
22. R.J. Barnard, J.A. Howe, R.A. Ogert, S. Zeuzem, F. Poordad, S.C. Gordon, R. Ralston, X. Tong, V. Sniukiene, and J. Strizki et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Virology 444 2013 329 336
23. J.C. Sullivan, S. De Meyer, D.J. Bartels, I. Dierynck, E.Z. Zhang, J. Spanks, A.M. Tigges, A. Ghys, J. Dorrian, and N. Adda et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials Clin Infect Dis 57 2013 221 229
24. X.V. Thomas, J. de Bruijne, J.C. Sullivan, T.L. Kieffer, C.K. Ho, S.P. Rebers, M. de Vries, H.W. Reesink, C.J. Weegink, and R. Molenkamp et al. Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir PLoS ONE 7 2012 e41191
25. O. Lenz, J. de Bruijne, L. Vijgen, T. Verbinnen, C. Weegink, H. Van Marck, I. Vandenbroucke, M. Peeters, K. Simmen, and G. Fanning et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy Gastroenterology 143 2012 1176-1178.e1-6
26. X. Tong, R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B.A. Malcolm Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antiviral Res 70 2006 28 38
27. L. Lagace, P.W. White, C. Bousquet, N. Dansereau, F. Do, M. Llinas-Brunet, M. Marquis, M.J. Massariol, R. Maurice, and C. Spickler et al. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335 Antimicrob Agents Chemother 56 2012 569 572
28. O. Lenz, T. Verbinnen, T.I. Lin, L. Vijgen, M.D. Cummings, J. Lindberg, J.M. Berke, P. Dehertogh, E. Fransen, and A. Scholliers et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob Agents Chemother 54 1878 1878 1887
29. O. Lenz, L. Vijgen, J.M. Berke, M.D. Cummings, B. Fevery, M. Peeters, G. De Smedt, C. Moreno, and G. Picchio Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202) J Hepatol 58 2013 445 451
30. K.L. Berger, I. Triki, M. Cartier, M. Marquis, M.J. Massariol, W.O. Bocher, Y. Datsenko, G. Steinmann, J. Scherer, and J.O. Stern et al. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir Antimicrob Agents Chemother 58 2014 698 705
31. D.J. Bartels, Y. Zhou, E.Z. Zhang, M. Marcial, R.A. Byrn, T. Pfeiffer, A.M. Tigges, B.S. Adiwijaya, C. Lin, and A.D. Kwong et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects J Infect Dis 198 2008 800 807
32. I. Vicenti, A. Rosi, F. Saladini, G. Meini, F. Pippi, B. Rossetti, L. Sidella, S. Di Giambenedetto, P. Almi, and A. De Luca et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy J Antimicrob Chemother 67 2012 984 987
33. N. Palanisamy, A. Danielsson, C. Kokkula, H. Yin, K. Bondeson, L. Wesslen, A.S. Duberg, and J. Lennerstrand Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a Antiviral Res 99 2013 12 17
34. S. Paolucci, L. Fiorina, B. Mariani, R. Gulminetti, S. Novati, G. Barbarini, R. Bruno, and F. Baldanti Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients Virol J 10 2013 355